Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by Bureau of Consumer Financial Protection relating to the withdrawal of the rule relating to "Debt Collection Practices (Regulation F); Deceptive and Unfair Collection of Medical Debt".
- Sponsor
- Rep. Pressley, Ayanna [D-MA-7]
- Committees
- Financial Services Committee (primary)
- Last action
- Apr 30, 2026
Bottom line
This resolution aims to prevent the Bureau of Consumer Financial Protection from rolling back consumer protections against aggressive medical debt collection practices.
What it actually does
This joint resolution utilizes the Congressional Review Act (CRA) to disapprove a rule issued by the Bureau of Consumer Financial Protection (BCFP). The BCFP rule in question (90 Fed. Reg. 20084, May 12, 2025) sought to withdraw an earlier BCFP rule (89 Fed. Reg. 80715, October 4, 2024) related to "Debt Collection Practices (Regulation F); Deceptive and Unfair Collection of Medical Debt." By disapproving the withdrawal rule, H.J. Res. 167 effectively prevents the BCFP from removing the original protections, thereby maintaining the safeguards against deceptive and unfair collection of medical debt.
Proponents argue
Proponents argue that the BCFP's attempt to withdraw protections against deceptive and unfair medical debt collection is detrimental to consumers, particularly vulnerable populations. They contend that medical debt is a significant burden for many Americans, and the original rule provided essential safeguards. Disapproving the withdrawal ensures these critical consumer protections remain in place, preventing predatory practices and alleviating financial stress for individuals facing medical bills.
Opponents contend
Opponents of this resolution (and by extension, proponents of the BCFP's withdrawal rule) would likely argue that the original medical debt collection rule imposed undue burdens on legitimate debt collectors and healthcare providers, potentially increasing operational costs or limiting their ability to recover legitimate debts. They might contend that the withdrawal was necessary to streamline regulations, reduce compliance costs, and ensure a more efficient debt collection market without stifling economic activity.
The bill text is extremely short and straightforward, requiring minimal time to read. However, understanding its full implications requires knowledge of the underlying BCFP rules it references.
Resolved by the Senate and House of Representatives... (May 12, 2025)), and such rule shall have no force or effect.
Congressional Disapproval of BCFP Rule Withdrawal
This provision explicitly states that Congress disapproves of the Bureau of Consumer Financial Protection's rule published on May 12, 2025, which aimed to withdraw an earlier rule on medical debt collection practices. By disapproving this withdrawal, the resolution effectively prevents the BCFP from removing the original protections, thereby keeping the safeguards against deceptive and unfair collection of medical debt in force.
Supporters argue
Supporters argue that maintaining the original rule is crucial for consumer financial well-being, preventing aggressive and misleading tactics that can push individuals further into financial distress due to medical emergencies. They emphasize that medical debt is often unexpected and can be particularly devastating.
Critics contend
Opponents of this disapproval (i.e., those who supported the BCFP's withdrawal) would argue that the original rule imposed unnecessary restrictions and costs on debt collectors and healthcare providers, potentially hindering their ability to recover legitimate debts and increasing the cost of healthcare services. They might contend that existing consumer protection laws are sufficient.
Tradeoffs
The resolution highlights the tension between consumer protection from potentially predatory debt collection practices and the operational flexibility and cost concerns of debt collection agencies and healthcare providers. It also reflects a broader debate on the appropriate scope of federal regulatory oversight in financial markets.